[
  {
    "ts": "2026-01-15T05:44:32+00:00",
    "headline": "3SBio Sees More Business Development Deals",
    "summary": "Tony He, CFO of the Chinese biopharmaceutical firm 3SBio, discusses his outlook for dealmaking and the progress of a record licensing deal the company struck with Pfizer last year. He speaks on \"Bloomberg: The China Show\" from San Francisco, where the JPMorgan Healthcare Conference is taking place.",
    "url": "https://finance.yahoo.com/video/3sbio-sees-more-business-development-054432609.html",
    "source": "Bloomberg",
    "provider": "yfinance",
    "raw": {
      "id": "cac7f054-28ad-3088-937d-3c9f8e775881",
      "content": {
        "id": "cac7f054-28ad-3088-937d-3c9f8e775881",
        "contentType": "VIDEO",
        "title": "3SBio Sees More Business Development Deals",
        "description": "Tony He, CFO of the Chinese biopharmaceutical firm 3SBio, discusses his outlook for dealmaking and the progress of a record licensing deal the company struck with Pfizer last year. He speaks on \"Bloomberg: The China Show\" from San Francisco, where the JPMorgan Healthcare Conference is taking place.",
        "summary": "Tony He, CFO of the Chinese biopharmaceutical firm 3SBio, discusses his outlook for dealmaking and the progress of a record licensing deal the company struck with Pfizer last year. He speaks on \"Bloomberg: The China Show\" from San Francisco, where the JPMorgan Healthcare Conference is taking place.",
        "pubDate": "2026-01-15T05:44:32Z",
        "displayTime": "",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/bloomberg_markets_video_2/fa7cc06b63421a215976d557a5147cb9",
          "originalWidth": 1280,
          "originalHeight": 720,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/lMRja4n.8RK5fv8Jkjxo7Q--~B/aD03MjA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/bloomberg_markets_video_2/fa7cc06b63421a215976d557a5147cb9.cf.webp",
              "width": 1280,
              "height": 720,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ftbssyNRiSeWM6dPjxAcMg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/bloomberg_markets_video_2/fa7cc06b63421a215976d557a5147cb9.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Bloomberg",
          "url": "https://www.bloomberg.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/video/3sbio-sees-more-business-development-054432609.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/video/3sbio-sees-more-business-development-054432609.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "TRSBF"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-15T12:22:02+00:00",
    "headline": "Factbox-Major deals involving U.S. drugmakers and biotechs over the past decade",
    "summary": "Jan 15 (Reuters) - Boston Scientific is buying medical equipment maker Penumbra in a deal valued at about $14.5 billion, to expand its vascular pipeline.",
    "url": "https://finance.yahoo.com/news/factbox-major-deals-involving-u-122202362.html",
    "source": "Reuters",
    "provider": "yfinance",
    "raw": {
      "id": "98831ded-5316-3639-8b32-bf5b84c462f3",
      "content": {
        "id": "98831ded-5316-3639-8b32-bf5b84c462f3",
        "contentType": "STORY",
        "title": "Factbox-Major deals involving U.S. drugmakers and biotechs over the past decade",
        "description": "",
        "summary": "Jan 15 (Reuters) - Boston Scientific is buying medical equipment maker Penumbra in a deal valued at about $14.5 billion, to expand its vascular pipeline.",
        "pubDate": "2026-01-15T12:22:02Z",
        "displayTime": "2026-01-15T12:22:02Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "Reuters",
          "url": "https://www.reuters.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/factbox-major-deals-involving-u-122202362.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/factbox-major-deals-involving-u-122202362.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PEN"
            },
            {
              "symbol": "BSX"
            },
            {
              "symbol": "EXAS"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "ABT"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-15T13:38:00+00:00",
    "headline": "Will DefenCath Continue to Aid CorMedix's Top Line in Q4 Earnings?",
    "summary": "CRMD's DefenCath, the only FDA-approved antimicrobial catheter lock, saw higher outpatient dialysis use in the fourth quarter, likely driving revenues.",
    "url": "https://finance.yahoo.com/news/defencath-continue-aid-cormedixs-top-133800523.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "19b5c4ae-c2f4-3d60-b4e6-d62037bc3807",
      "content": {
        "id": "19b5c4ae-c2f4-3d60-b4e6-d62037bc3807",
        "contentType": "STORY",
        "title": "Will DefenCath Continue to Aid CorMedix's Top Line in Q4 Earnings?",
        "description": "",
        "summary": "CRMD's DefenCath, the only FDA-approved antimicrobial catheter lock, saw higher outpatient dialysis use in the fourth quarter, likely driving revenues.",
        "pubDate": "2026-01-15T13:38:00Z",
        "displayTime": "2026-01-15T13:38:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/TNBAnrhWOnvvvNSvMEIuFg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/rP7ZEHNft_Sb_FB9M.3i3w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/defencath-continue-aid-cormedixs-top-133800523.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/defencath-continue-aid-cormedixs-top-133800523.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "CRMD"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-15T16:40:01+00:00",
    "headline": "Why Pfizer Inc. (PFE) is One of the Best Affordable Stocks Under $30",
    "summary": "Pfizer Inc. (NYSE:PFE) is one of the best affordable stocks under $30. Pfizer Inc. (NYSE:PFE) announced on January 10 positive results from Cohort 3, which is a separate randomized cohort of the pivotal BREAKWATER trial, evaluating BRAFTOVI® in combination with cetuximab and FOLFIRI in patients with previously untreated metastatic colorectal cancer with a BRAF V600E […]",
    "url": "https://finance.yahoo.com/news/why-pfizer-inc-pfe-one-164001107.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "cab6d01b-a070-3f9e-a0fd-f72a9dccf137",
      "content": {
        "id": "cab6d01b-a070-3f9e-a0fd-f72a9dccf137",
        "contentType": "STORY",
        "title": "Why Pfizer Inc. (PFE) is One of the Best Affordable Stocks Under $30",
        "description": "",
        "summary": "Pfizer Inc. (NYSE:PFE) is one of the best affordable stocks under $30. Pfizer Inc. (NYSE:PFE) announced on January 10 positive results from Cohort 3, which is a separate randomized cohort of the pivotal BREAKWATER trial, evaluating BRAFTOVI® in combination with cetuximab and FOLFIRI in patients with previously untreated metastatic colorectal cancer with a BRAF V600E […]",
        "pubDate": "2026-01-15T16:40:01Z",
        "displayTime": "2026-01-15T16:40:01Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/aef4b35e5ea946bf7f4ed347e5c4f487",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "UBS Likes Pfizer’s MTSR Obesity Deal but Stays Neutral on PFE",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/UKiv8LHLxutAA7dDIzr_pw--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/aef4b35e5ea946bf7f4ed347e5c4f487.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/1v0rnd.QZj0de1gLzaNuAg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/aef4b35e5ea946bf7f4ed347e5c4f487.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/why-pfizer-inc-pfe-one-164001107.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/why-pfizer-inc-pfe-one-164001107.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]